In a 3-0 ruling, the 3rd US Circuit Court of Appeals in Philadelphia restored the claims of several hundreds of plaintiffs against Merck for their osteoporosis drug Fosamax, according to Reuters. The plaintiffs claim the company didn’t adequately warn of the risk of thigh bone fractures that the drug may carry. Trials can now proceed on failure-to-warn claims, which a lower court originally found to be pre-empted ...
Appeals Court Restores Cases Against Merck Over Fosamax
Posted May 2, 2017 in Drug and Medical Device Lawsuits | Product News and Recalls
Merck Faces 3rd Rejection of Anesthesia Drug
Posted April 3, 2015 in Drug and Medical Device Lawsuits | Product News and Recalls
The pharmaceutical giant Merck faces yet another FDA rejection of its anesthesia drug Sugammadex, FierceBiotech reports. Sugammadex, obtained when Merck merged with the pharmaceutical company Shering-Plough, has been hailed as one of the top experimental drugs in Merck’s development pipeline. Over the years, however, it has experienced a number of setbacks, beginning with its first rejection by the FDA in 2008 and continuing ...
Plaintiffs Reject Their Part Of $100 Million NuvaRing Settlement
Posted August 20, 2014 in Drug and Medical Device Lawsuits | Product News and Recalls | Verdicts & Settlements
A $100 million settlement with Merck & Co. has been finalized as 95 percent of claimants opted to receive compensation. The settlement regarding the company’s hormonal contraceptive, NuvaRing, was announced in February. There will be about 3,800 people that will receive compensation through the NuvaRing settlement.
The NuvaRing lawsuits alleged that Merck had downplayed the health risks connected to the contraceptive and did not adequately warn its users about the potential serious complications. ...
continue reading...Merck to Settle NuvaRing Intrauterine Contraceptive Device Lawsuits
Posted February 10, 2014 in Drug and Medical Device Lawsuits | Product News and Recalls | Verdicts & Settlements
On Friday, February 7, 2014, Merck & Co announced that it is willing to pay $100 million to settle all NuvaRing intrauterine contraceptive device lawsuits.
The NuvaRing contraceptive is a flexible ring that releases the hormones estrogen and progestin in order to prevent pregnancy. NuvaRing has been associated with an increased risk of forming blood clots, which can in turn cause heart attacks, strokes, even death. An FDA report released in 2011 announced that NuvaRing posed a higher risk for blood ...
continue reading...
